The Department of Cardiology, Shenzhen Children's Hospital, Shenzhen, China.
The Department of Pharmacology, Clinical Translational Center for Targeted Drug, School of Medicine, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangdong, China.
Vascul Pharmacol. 2020 Apr;127:106660. doi: 10.1016/j.vph.2020.106660. Epub 2020 Feb 15.
Kawasaki disease (KD) is an acute febrile illness characterized by systemic vasculitis especially in coronary arteries. Berberine (BBR) shows several beneficial effects on cardiovascular system. The present study is to investigate whether BBR exerts protective effect against KD-induced damage of human coronary artery endothelial cell (HCAECs) and the underlying mechanisms. HCAECs exposed to medium with 15% serum from KD patients or healthy volunteers for 24 h. Stimulated HCAECs were treated with vehicle (without BBR) and BBR (20 μM) for 24 h, the cell apoptosis, cell cycle, induction of intracellular reactive oxygen species (ROS) and protein expression were examined by flow cytometry and western blot. The KD-induced differentially expressed proteins in HCAECs were determined by quantitative proteomics. BBR inhibited HCAECs from apoptosis and arrested cell cycle at G0/G1 stage. BBR protected HCAECs from injury by inhibiting expression of THBD, vWF and EDN1. Bioinformatics analysis suggested that the oxidative and ER stress were involved in KD-induced damage in HCAECs. ROS production and the protein expression of ATF4, p-EIF2α, p-PERK, XBP1, p-IRE1, HSP90B1, HSPG2, DNAJC3, P4HB and VCP were increased by serum from KD patients and decreased by BBR treatment. BBR exerts its protective effects on KD-induced damage of HCAECs through its inhibitory effects on oxidative and ER stress indicating BBR as a therapeutic candidate for KD.
川崎病(KD)是一种以全身血管炎为特征的急性发热性疾病,尤其是在冠状动脉。小檗碱(BBR)对心血管系统有多种有益作用。本研究旨在探讨 BBR 是否对川崎病患者诱导的人冠状动脉内皮细胞(HCAECs)损伤具有保护作用及其机制。将 HCAECs 暴露于含有 15%KD 患者或健康志愿者血清的培养基中 24 小时。用载体(无 BBR)和 BBR(20 μM)处理刺激的 HCAECs 24 小时,通过流式细胞术和 Western blot 检测细胞凋亡、细胞周期、细胞内活性氧(ROS)诱导和蛋白表达。通过定量蛋白质组学检测 HCAECs 中 KD 诱导的差异表达蛋白。BBR 抑制 HCAECs 凋亡并将细胞周期阻滞在 G0/G1 期。BBR 通过抑制 THBD、vWF 和 EDN1 的表达来保护 HCAECs 免受损伤。生物信息学分析表明,氧化应激和内质网应激参与了 HCAECs 中 KD 诱导的损伤。KD 患者血清增加了 ROS 产生和 ATF4、p-EIF2α、p-PERK、XBP1、p-IRE1、HSP90B1、HSPG2、DNAJC3、P4HB 和 VCP 的蛋白表达,而 BBR 处理则降低了这些蛋白的表达。BBR 通过抑制氧化应激和内质网应激对 KD 诱导的 HCAECs 损伤发挥保护作用,表明 BBR 可作为 KD 的治疗候选药物。